Nordic Nanovector ASA: Increased share capital following exercise of employee share options

Oslo, Norway, 16 November 2018.

A individual participant in Nordic Nanovector ASA's (the "Company") (OSE:NANO) previous share option program, not being a primary insider, has exercised a total number of 300,000 options through exercise of a corresponding number of free-standing warrants. 185,421 of the options are exercised at a strike price of NOK 25 per share, and 114,579 of the options are exercised at a strike price of NOK 14.24 per share. Each free-standing warrant gives the right to receive one share in the Company.

Following exercise of the 300,000 free-standing warrants, the Company's registered share capital was increased by NOK 60,000 through issuance of 300,000 new shares, each with a nominal value of NOK 0.20, against payment of a total subscription price of NOK 6,267,130. Following the share capital increase the Company has a share capital of NOK 9,884,503 divided on 49,422,515 shares, each with a par value of NOK 0.20.

For further information, please contact:
Malene Brondberg,
VP Investor Relations and Corporate Communications
Cell: +44 7561 431 762
Email: ir@nordicnanovector.com

About Nordic Nanovector:
Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information about the Company can be found at www.nordicnanovector.com
This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

 

Tags:

About Us

About Nordic Nanovector Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The Company aspires to become a leader in the development of targeted therapies for haematological cancers. Nordic Nanovector's lead clinical-stage candidate is Betalutin®, a novel CD37-targeting antibody-radionuclide-conjugate designed to advance the treatment of non-Hodgkin's lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 29 billion by 2026. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets. Further information can be found at www.nordicnanovector.com. This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Subscribe